Health Care Disparities and the Future of Pancreatic Cancer Care

2021 ◽  
Vol 30 (4) ◽  
pp. 759-771
Author(s):  
Marianna V. Papageorge ◽  
Douglas B. Evans ◽  
Jennifer F. Tseng
Keyword(s):  
Health Care ◽  
Pancreatic Cancer ◽  
Cancer Care ◽  
Health Care Disparities ◽  
The Future

Mental Health Care Disparities Now and in the Future

2017 ◽  
Vol 5 (2) ◽  
pp. 351-356
Author(s):  
Rahn Bailey ◽  
Daphne Sharpe ◽  
Tricia Kwiatkowski ◽  
Susanne Watson ◽  
A . Dexter Samuels ◽  
...  
Keyword(s):  
Mental Health ◽  
Health Care ◽  
Mental Health Care ◽  
Health Care Disparities ◽  
The Future

scholarly journals The Association between Mortality-to-Incidence Ratios and Health Expenditures in Brain and Nervous System Cancers

2019 ◽  
Vol 16 (15) ◽  
pp. 2739
Author(s):  
Lee ◽  
Sung ◽  
Chan ◽  
Lee ◽  
Chen ◽  
...  
Keyword(s):  
Health Care ◽  
Pancreatic Cancer ◽  
Nervous System ◽  
Human Development ◽  
Human Development Index ◽  
Health Care Disparities ◽  
Health Care Systems ◽  
Rank Correlation ◽  
Health Expenditures ◽  
Development Index

Mortality-to-incidence ratios (MIRs) are alternative parameters used to evaluate the prognosis of a disease. In addition, MIRs are associated with the ranking of health care systems and expenditures for certain types of cancer. However, a lack of association between MIRs and pancreatic cancer has been noted. Given the poor prognosis of brain and nervous system cancers, similar to pancreatic cancer, the relation of MIRs and health care disparities is worth investigating. We used the Spearman’s rank correlation coefficient (CC) to analyze the correlation between the MIRs in brain and nervous system cancers and inter-country disparities, including expenditures on health and human development index. Interestingly, the MIRs in brain and nervous system cancers are associated with the human development index score (N = 157, CC = −0.394, p < 0.001), current health expenditure (CHE) per capita (N = 157, CC = −0.438, p < 0.001), and CHE as percentage of gross domestic product (N = 157, CC = −0.245, p = 0.002). In conclusion, the MIRs in the brain and nervous system cancer are significantly associated with health expenditures and human development index. However, their role as an indicator of health disparity warrants further investigation.

scholarly journals Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes

2021 ◽  
pp. 1-13
Author(s):  
Raymond U. Osarogiagbon ◽  
Helmneh M. Sineshaw ◽  
Joseph M. Unger ◽  
Ana Acuña-Villaorduña ◽  
Sanjay Goel
Keyword(s):  
Health Care ◽  
Social Policy ◽  
Health Care System ◽  
Cancer Care ◽  
Health Care Disparities ◽  
Routine Care ◽  
Individual Level ◽  
Oncology Research ◽  
The Individual ◽  
Care System

Avoidable differences in the care and outcomes of patients with cancer (i.e., cancer care disparities) emerge or worsen with discoveries of new, more effective approaches to cancer diagnosis and treatment. The rapidly expanding use of immunotherapy for many different cancers across the spectrum from late to early stages has, predictably, been followed by emerging evidence of disparities in access to these highly effective but expensive treatments. The danger that these new treatments will further widen preexisting cancer care and outcome disparities requires urgent corrective intervention. Using a multilevel etiologic framework that categorizes the targets of intervention at the individual, provider, health care system, and social policy levels, we discuss options for a comprehensive approach to prevent and, where necessary, eliminate disparities in access to the clinical trials that are defining the optimal use of immunotherapy for cancer, as well as its safe use in routine care among appropriately diverse populations. We make the case that, contrary to the traditional focus on the individual level in descriptive reports of health care disparities, there is sequentially greater leverage at the provider, health care system, and social policy levels to overcome the challenge of cancer care and outcomes disparities, including access to immunotherapy. We also cite examples of effective government-sponsored and policy-level interventions, such as the National Cancer Institute Minority-Underserved Community Oncology Research Program and the Affordable Care Act, that have expanded clinical trial access and access to high-quality cancer care in general.

Are You Ready to Shape the Future of Health Care?

ASHA Leader ◽  
2011 ◽  
Vol 16 (6) ◽  
pp. 9-9
Author(s):  
Paul R. Rao
Keyword(s):  
Health Care ◽  
The Future
Sign in / Sign up

Export Citation Format

Share Document